Literature DB >> 30911631

A new ex vivo model for optimizing distribution of therapeutic aerosols: the (inverted) bovine urinary bladder.

Daniel Schnelle1, Frank-Jürgen Weinreich1, Janek Kibat1, Marc A Reymond1.   

Abstract

BACKGROUND: Development of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) requires adequate preclinical models.
METHODS: The model should be easy to use, reproducible and cost-effective. It should have a volume similar to the human abdominal cavity, and an oval shape. The inner surface should be lined with serosa. The model should allow pharmacological and biological analysis, including histology. No living animals should be used.
RESULTS: The fresh urinary bladder is explanted from an adult bovine in the slaughterhouse. A 4-cm incision is performed into the bladder neck. The bladder can be inverted through the incision, which allows exposition of the serosa on its inner side. A balloon trocar is inserted through the incision and a ligature placed, ensuring full tightness. The therapeutic capnoperitoneum is installed. The bovine bladder has a volume somewhat smaller (2-3 L) than the human abdominal cavity (3-5 L). Costs are minimal. There is no significant bacteriological contamination. Manipulation is simple.
CONCLUSIONS: The (inverted) bovine urinary bladder is an innovative and versatile ex vivo model for optimizing drug delivery with therapeutic aerosols both onto the mucosa or the serosa. This model can be used for pharmaceutical Quality-by-Design approaches and will replace a large number of experiments in the animal.

Entities:  

Keywords:  Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC); animal model; intraperitoneal chemotherapy; urinary bladder

Year:  2017        PMID: 30911631      PMCID: PMC6328072          DOI: 10.1515/pp-2017-0006

Source DB:  PubMed          Journal:  Pleura Peritoneum        ISSN: 2364-768X


  10 in total

1.  Description of a novel approach for intraperitoneal drug delivery and the related device.

Authors:  Wiebke Solaß; Alexander Hetzel; Giorgi Nadiradze; Emil Sagynaliev; Marc A Reymond
Journal:  Surg Endosc       Date:  2012-05-12       Impact factor: 4.584

2.  Pressurized intraluminal aerosol chemotherapy with Dbait in the distal esophagus of swine.

Authors:  Nadja Khalili-Harbi; Nirmitha Herath; Wiebke Solass; Urs Giger-Pabst; Marie Dutreix; Marc Andre Reymond
Journal:  Endoscopy       Date:  2015-10-13       Impact factor: 10.093

3.  Small-solute transport across specific peritoneal tissue surfaces in the rat.

Authors:  M F Flessner
Journal:  J Am Soc Nephrol       Date:  1996-02       Impact factor: 10.121

4.  Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model.

Authors:  Veria Khosrawipour; Tanja Khosrawipour; Alexander Jens Peter Kern; Aras Osma; Burak Kabakci; David Diaz-Carballo; Eckart Förster; Jürgen Zieren; Khashayar Fakhrian
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-02       Impact factor: 4.553

5.  Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study.

Authors:  Clemens B Tempfer; Guido Winnekendonk; Wiebke Solass; Reinhard Horvat; Urs Giger-Pabst; Juergen Zieren; Guenther A Rezniczek; Marc-André Reymond
Journal:  Gynecol Oncol       Date:  2015-02-18       Impact factor: 5.482

6.  Exploring the Spatial Drug Distribution Pattern of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).

Authors:  Veria Khosrawipour; Tanja Khosrawipour; David Diaz-Carballo; Eckart Förster; Jürgen Zieren; Urs Giger-Pabst
Journal:  Ann Surg Oncol       Date:  2015-11-09       Impact factor: 5.344

7.  Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept.

Authors:  Wiebke Solass; Aurélie Herbette; Tina Schwarz; Alexander Hetzel; Jian-Sheng Sun; Marie Dutreix; Marc A Reymond
Journal:  Surg Endosc       Date:  2011-11-01       Impact factor: 4.584

8.  Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy.

Authors:  Wiebke Solass; Reinhold Kerb; Thomas Mürdter; Urs Giger-Pabst; Dirk Strumberg; Clemens Tempfer; Jürgen Zieren; Matthias Schwab; Marc André Reymond
Journal:  Ann Surg Oncol       Date:  2013-09-05       Impact factor: 5.344

Review 9.  Gut microbiome, surgical complications and probiotics.

Authors:  George Stavrou; Katerina Kotzampassi
Journal:  Ann Gastroenterol       Date:  2016-09-06

10.  In Vivo Feasibility of Electrostatic Precipitation as an Adjunct to Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC).

Authors:  Tinatin Kakchekeeva; Cedric Demtröder; Nirmitha I Herath; Dominic Griffiths; Jared Torkington; Wiebke Solaß; Marie Dutreix; Marc A Reymond
Journal:  Ann Surg Oncol       Date:  2016-02-02       Impact factor: 5.344

  10 in total
  10 in total

Review 1.  Is PIPAC a Treatment Option in Upper and Lower Gastrointestinal Cancer with Peritoneal Metastasis?

Authors:  Safak Guel-Klein; Miguel Enrique Alberto Vilchez; Wim Ceelen; Beate Rau; Andreas Brandl
Journal:  Visc Med       Date:  2022-03-21

2.  PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial.

Authors:  Mustafa Raoof; Gautam Malhotra; Adrian Kohut; Michael O'Leary; Paul Frankel; Thuy Tran; Marwan Fakih; Joseph Chao; Dean Lim; Yanghee Woo; Isaac B Paz; Michael Lew; Mihaela C Cristea; Lorna Rodriguez-Rodriguez; Yuman Fong; Andrew Blakely; Richard Whelan; Marc A Reymond; Amit Merchea; Thanh H Dellinger
Journal:  Ann Surg Oncol       Date:  2021-08-13       Impact factor: 5.344

3.  Establishment of a rat ovarian peritoneal metastasis model to study pressurized intraperitoneal aerosol chemotherapy (PIPAC).

Authors:  Leen Van de Sande; Wouter Willaert; Sarah Cosyns; Kaat De Clercq; Molood Shariati; Katrien Remaut; Wim Ceelen
Journal:  BMC Cancer       Date:  2019-05-07       Impact factor: 4.430

4.  Influence of pre-analytical sample preparation on drug concentration measurements in peritoneal tissue: an ex-vivo study.

Authors:  Arianna Castagna; Iaroslav Sautkin; Frank-Jürgen Weinreich; Hannah Heejung Lee; Alfred Königsrainer; Marc André Reymond; Giorgi Nadiradze
Journal:  Pleura Peritoneum       Date:  2021-07-28

5.  Development of a rat capnoperitoneum phantom to study drug aerosol deposition in the context of anticancer research on peritoneal carcinomatosis.

Authors:  Daniel Göhler; Ralf Gritzki; Antje Geldner; Franz Lohse; Stephan Große; Julien Sobilo; Clemens Felsmann; Jonathan R Buggisch; Alain Le Pape; Andreas Rudolph; Michael Stintz; Urs Giger-Pabst
Journal:  Sci Rep       Date:  2021-11-08       Impact factor: 4.379

6.  Optimization of intraperitoneal aerosolized drug delivery using computational fluid dynamics (CFD) modeling.

Authors:  Mohammad Rahimi-Gorji; Charlotte Debbaut; Ghader Ghorbaniasl; Sarah Cosyns; Wouter Willaert; Wim Ceelen
Journal:  Sci Rep       Date:  2022-04-15       Impact factor: 4.996

7.  Feasibility of pressurized intra peritoneal aerosol chemotherapy using an ultrasound aerosol generator (usPIPAC).

Authors:  Phil Höltzcke; Iaroslav Sautkin; Samuel Clere; Arianna Castagna; Alfred Königsrainer; Peter P Pott; Marc A Reymond
Journal:  Surg Endosc       Date:  2022-08-29       Impact factor: 3.453

8.  A real-time ex vivo model (eIBUB) for optimizing intraperitoneal drug delivery as an alternative to living animal models.

Authors:  Iaroslav Sautkin; Wiebke Solass; Frank-Jürgen Weinreich; Alfred Königsrainer; Martin Schenk; Karolin Thiel; Marc A Reymond
Journal:  Pleura Peritoneum       Date:  2019-08-15

Review 9.  Pressurized intraperitoneal aerosol chemotherapy: a review of the introduction of a new surgical technology using the IDEAL framework.

Authors:  S J Tate; J Torkington
Journal:  BJS Open       Date:  2020-01-19

10.  Technology development of hyperthermic pressurized intraperitoneal aerosol chemotherapy (hPIPAC).

Authors:  C Bachmann; I Sautkin; G Nadiradze; R Archid; F J Weinreich; A Königsrainer; M A Reymond
Journal:  Surg Endosc       Date:  2021-06-10       Impact factor: 4.584

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.